AskBio Inc., a gene therapy company and a subsidiary of Bayer AG, has introduced its commercially ready manufacturing process to supply ametefgene parvec (AB-1005), an investigational gene therapy for the treatment of Parkinson’s disease (PD) and multiple system atrophy-parkinsonian type (MSA-P), following submission of a U.S. FDA Investigational New Drug Application (IND) amendment.   This enables AskBio to advance its REGENERATE-PD Phase II clinical trial in the U. S. with the material prod...